Have an open convo with your provider, weigh your options honestly, and remember: the goal isnt just to lose weightits to feel better while doing it
* Reduced meal volume
The study population comprised 1,248 individuals in the Liraglutide group and 2,104 individuals in the Semaglutide group, with males accounting for 1,594 individuals, constituting 47.5% of the total population
Insulin syringes, for the small volumes
[1] Baseline Cardiovascular Profile The SELECT study is a large cardiovascular outcomes trial designed to assess whether semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), can reduce cardiovascular events in people who are overweight or obese but do not have diabetes
The first reconstitution and the first injection are taught in person, not over video